Skip to content

Psychedelic-assisted therapy research published in 2022

Page 2 of 5: studies 21 to 40 of 84, newest first. Back to the psychedelic-assisted therapy overview

Studies

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Frontiers in Psychiatry October 12, 2022 Robert J Sottile, Thomas Vida 30 citations

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease....

MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials

Frontiers in Psychiatry October 10, 2022 Christopher S. Stauffer, Melanie Brown, Dee Adams et al. 40 citations

Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the...

DOI: 10.3389/fpsyt.2022.932605 (opens in new tab) MDMA Mental health Transgender Clinical psychology +5

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.

Transcultural Psychiatry October 1, 2022 Christopher Timmermann, Rosalind Watts, David Dupuis 112 citations

A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced, which may persist long after psychedelic effects have subsided. We propose that processes underlying conferral of meaning and truth in psychedelic experiences may act as a double-edged sword: while these may drive important therapeutic benefits,...

Preparing for the Bursting of the Psychedelic Hype Bubble.

JAMA Psychiatry October 1, 2022 David B. Yaden, James B. Potash, Roland R. Griffiths 153 citations

This Viewpoint presents impediments to the clinical application of psychedelics created by extreme shifts in public perception while advocating further study and encouraging the dispute of claims not supported by available evidence.

DOI: 10.1001/jamapsychiatry.2022.2546 (opens in new tab) Psychedelic therapy Psychedelic medicine Entheogenic treatment Hallucinogen-assisted therapy +10

The Emerging Field of Psychedelic Psychotherapy.

Current Psychiatry Reports October 1, 2022 Gregory S. Barber, Scott T Aaronson 56 citations

Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as...

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)

BMJ Open October 1, 2022 Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul et al. 21 citations

Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meaningful experiences that may spur a positive change in drinking behaviour when administered in a...

Potential Therapeutic Effects of Psilocybin: A Systematic Review.

Cureus October 1, 2022 Dev B Goel, Sarju Zilate 24 citations

Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...

MDMA-Assisted Psychotherapy for Borderline Personality Disorder.

FOCUS: The Journal of Lifelong Learning in Psychiatry October 1, 2022 Jenna M Traynor, Daniel E. Roberts, Stephen Ross et al. 14 citations

Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on...

DOI: 10.1176/appi.focus.20220056 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted psychotherapy Borderline personality disorder Drug treatment/psychopharmacology MDMA-Assisted Psychotherapy +4

Commentary: Psychedelics and psychotherapy: Cognitive-behavioral approaches as default

Frontiers in Psychology September 30, 2022 John Burton, Austin Ratner, Timothy Cooper et al.

GENERAL COMMENTARY article Front. Psychol., 30 September 2022Sec. Psychology for Clinical Settings Volume 13 - 2022 | https://doi.org/10.3389/fpsyg.2022.1020222

Knowing and being known: Psychedelic–assisted psychotherapy and the sense of authenticity

Frontiers in Psychiatry September 20, 2022 Lawrence Fischman 9 citations

Participants in MDMA- and psychedelic-assisted psychotherapy often emerge from these treatments with new beliefs about themselves and the world. Studies have linked changed beliefs with mystical experiences reported by some participants during drug sessions. While there has been some debate about the epistemic value of drug-induced mystical experiences, and about the need for consent to...

Psychedelic drugs for psychiatric disorders.

Journal of the Neurological Sciences September 15, 2022 Sabrina Correa Da Costa, Tyler Oesterle, Teresa A Rummans et al. 21 citations

Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and...

Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.

Neuropharmacology September 15, 2022 S Ross, M Agrawal, Roland R. Griffiths et al. 69 citations

Psychiatric and existential distress commonly occur in advanced cancer and other serious, life-threatening or end-of-life medical illnesses and are associated with poor medical and psychiatric outcomes. Currently available treatment modalities in this patient population, including medication and psychotherapy, are limited in effectiveness, especially regarding existential distress. The lack of...

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder.

Neuropsychopharmacology September 1, 2022 Deepak Cyril D'Souza, Shariful A. Syed, L Taylor Flynn et al. 156 citations

There is considerable interest in the therapeutic potential of psychedelic drugs. Dimethyltryptamine (DMT) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been independently tested for the treatment of depression. The safety, tolerability, and efficacy of intravenous DMT were investigated in treatment-resistant individuals with major depressive disorder (MDD) and...

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.

Cureus September 1, 2022 Joshua S Kurtz, Neal A Patel, Julian L Gendreau et al. 35 citations

Although early therapeutic research on psychedelics dates back to the 1940s, this field of investigation was met with many cultural and legal challenges in the 1970s. Over the past two decades, clinical trials using psychedelics have resumed. Therefore, the goal of this study was to (1) better characterize the recent uptrend in psychedelics in clinical trials and (2) identify areas where...

Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.

Psychiatria Polska August 31, 2022 Sandra Szafoni, Gniewko Więckiewicz, Robert Pudło et al. 9 citations

Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended various therapeutic approaches, including both pharmacotherapy and psychotherapy, treatment is not as effective as expected. Over recent years the pharmaceutical industry has not been able to offer a new approach, founded on multiple mechanisms of...

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

JAMA Psychiatry August 24, 2022 Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. 668 citations

Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...

Review of potential psychedelic treatments for PTSD.

Journal of the Neurological Sciences August 15, 2022 Ryan L Henner, Matcheri S Keshavan, Kevin P Hill

Post-traumatic stress disorder (PTSD) is a debilitating mental illness with limited treatment options and a high treatment dropout rate. Psychedelics, often in combination with psychotherapy, are now under investigation as a potential treatment option for a variety of psychiatric conditions including PTSD. This paper reviews the proposed mechanism of action for 3,4-Methylenedioxymethamphetamine...

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Psychopharmacology August 8, 2022 Rosalind Watts, Hannes Kettner, Dana Geerts et al. 159 citations

Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to...

Psychedelic integration: An analysis of the concept and its practice

Frontiers in Psychology August 4, 2022 Geoff J. Bathje, Eric Majeski, Mesphina Kudowor 154 citations

The concept of integration has garnered increased attention in the past few years, despite a long history of only brief mention. Integration services are offered by therapists, coaches, and other practitioners, or may be self-guided. There are many definitions of psychedelic integration, and the term encompasses a range of practices and techniques. This seems to have led to confusion about what...

DOI: 10.3389/fpsyg.2022.824077 (opens in new tab) Psychedelic therapy Psychedelic assisted therapy Psychedelic integration: integration Entheogen integration +15

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

Journal of Palliative Medicine August 1, 2022 William E Rosa, Zachary Sager, Megan Miller et al. 49 citations

Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...